Gain Therapeutics, Inc. (GANX)
- GlobeNewswire
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
BETHESDA, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces positive results from the single ascending dose (SAD) part of its Phase 1 study. GT-02287 was generally well tolerated up to and including the highest planned dose level, and there were no serious adverse events. The good safety and
- Zacks
Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for Gain Therapeutics (GANX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
- Insider Monkey
Insiders are Piling into These 10 Healthcare Stocks in 2024
In this article, we will take a detailed look at Insiders are Piling into These 10 Healthcare Stocks in 2024. For a quick overview of such stocks, read our article Insiders are Piling into These 5 Healthcare Stocks in 2024. Healthcare investors were nervous when 2024 started, since election years usually don’t bode well for healthcare stocks. But […]
